Pediatric Dermatology News

• Impact of Pregnancy on Rosacea Unpredictable, Study Suggests Nearly half of study participants reported that their rosacea worsened when they were pregnant.
  Medscape Medical News, January 05, 2024
• Expert Highlights Biologics in the Pipeline for Eczema Dr David Rosmarin reviewed several biologics in clinical trials that target interleukin-4 and other receptors.
  MDedge News, January 05, 2024
• Assessing Patients With AD: Tools to Use in the Office "It can be overwhelming because there are many choices but so little time," says Dr Jonathan Silverberg, of George Washington University, Washington, DC.
  MDedge News, January 04, 2024
• Experimental Topical Drug Shows Promise for AD, Psoriasis In the phase 2 study, researchers at 34 sites in four countries randomized 104 patients with mild to moderate AD or psoriasis to receive the topical PDE4 inhibitor or a vehicle once daily for 6 weeks.
  MDedge News, January 04, 2024
• 5-Year Safety Data From Upadacitinib Trials Reported Upadacitinib trials in atopic dermatitis have included diverse patient groups with varying risk factors, according to Dr Christopher Bunick.
  MDedge News, January 03, 2024
• Conjunctivitis: How Common Is It in Patients on Dupilumab? Adults with AD have a significant and disease severity–dependent increased risk of developing ocular surface diseases, including conjunctivitis and keratitis.
  MDedge News, December 29, 2023
• Paradoxical Eczema Risk Low With Biologic Psoriasis Tx Ali Al-Janabi, MA, and associates found that 273 (1%) of approximately 25,000 drug exposures in 13,699 biologic-treated patients with psoriasis were associated with paradoxical eczema.
  MDedge News, December 22, 2023
• Reducing CVD Morbidity and Mortality in Psoriasis and PsA Only a minority of patients with psoriatic disease know about their increased risks.
  MDedge News, December 20, 2023
• How Does Lebrikizumab Perform Across Different Subgroups? Key eligibility criteria for both trials included adults or adolescents with a diagnosis of AD as defined by the AAD consensus criteria, for at least 1 year prior to screening.
  MDedge News, December 18, 2023
• Disease Control Elusive for Many Patients on AD Therapies A significant number of patients with moderate to severe atopic dermatitis (AD) failed to achieve adequate disease control with systemic therapies over 12 months, indicating a substantial degree of "therapeutic inertia."
  MDedge News, December 14, 2023
• Acne in Primary Care: The Best of Times? The repackaging of old medications into new formulations that are easier on the skin, and the availability of combination drug creams, should improve acne care.
  Medscape Medical News, December 13, 2023
• Acne Stigma Persists Across Social and Professional Settings Individuals with severe acne were considered less attractive, less worthy of friendship, and less likely to be hired for a job compared with those who did not have acne.
  MDedge News, December 12, 2023
• Bimekizumab Promising for Palmoplantar Pustular Psoriasis PPP is a type of pustular psoriasis that remains a treatment challenge, and available treatments for palmoplantar plaque psoriasis with pustules also "remain unsatisfactory."
  MDedge News, December 12, 2023
• Tape Strips Detect Hidradenitis Suppurativa Biomarkers "Tape strips can provide important clues to when and which drugs to use in HS in patients with both early and late disease, which can change clinical practice."
  MDedge News, December 08, 2023
• Patients With hEDS Report Skin Laxity, Scarring Follicular occlusion, mast cell disease, and eczema were common presentations among patients with hypermobile Ehlers-Danlos syndrome.
  MDedge News, December 07, 2023
• How Can Dermatologists Improve Cancer Care? Dermatologists play a key role on interdisciplinary treatment teams.
  Medscape Medical News, December 06, 2023
• Hope Emerges for Patients With Rare Skin Disorder "A new framework for thinking about and treating these diseases is emerging."
  Medscape Medical News, December 05, 2023
• MSWS 2023 What's New in Acne Treatment? Advances in acne care include the use of light-based devices.
  Medscape Medical News, December 04, 2023
• MSWS 2023 Misdiagnoses Among Challenges in Managing Cutaneous Lymphoma Although predictive tools to identify those at risk of disease progression are in their infancy, the development of such tools is crucial for improving patient outcomes.
  Medscape Medical News, December 02, 2023
• EADV 2023 Novel Subcutaneous Biologics Show Promise in AD Patients with moderate to severe atopic dermatitis could soon have more therapeutic options, with monoclonal antibodies targeting novel immune pathways that reduce disease severity, suggest two trials.
  Medscape Medical News, December 01, 2023
• Meta-Analysis: Suicide Risk Not Increased With Isotretinoin In fact, those treated with the drug for severe acne may have a lower risk for suicide attempts 2-4 years after treatment, according to the study authors.
  MDedge News, December 01, 2023
• Tapinarof Effective for AD in Patients as Young as 2 years Tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, was approved in 2022 for treating plaque psoriasis in adults.
  MDedge News, November 28, 2023
• EADV 2023 At 52 Weeks, Hair Growth Still Climbing on Deuruxolitinib With response curves still climbing at follow-up to date, the results are 'truly, truly remarkable.'
  MDedge News, November 28, 2023
• Parent Concerns a Factor When Treating Patients With AD For a parent whose child has an inflammatory skin disease, pigmentation changes, rather than inflammation, might be the reason that he or she brought the child to the clinician.
  MDedge News, November 23, 2023
• Questionnaire Measures Patient Satisfaction With Acne Tx A dermatology-specific questionnaire assessed three aspects of treatment in patients with acne.
  Medscape Medical News, November 22, 2023
• Lebrikizumab Gets the Nod in the EU for Atopic Dermatitis Lebrikizumab, an interleukin-13 inhibitor, is not yet approved in the United States.
  MDedge News, November 20, 2023
• EADV 2023 Vitiligo: 'Impressive' Results for Povorcitinib, Baricitinib Substantial facial and total body repigmentation in patients with nonsegmental vitiligo was achieved in separate trials of povorcitinib and baricitinib plus phototherapy.
  Medscape Medical News, November 08, 2023
• EADV 2023 Topical Ivermectin Study Sheds Light on Dysbiosis in Rosacea Study findings show that ivermectin reduces the density of Demodex folliculorum in rosacea lesions, but the skin microbiome takes time to recover.
  Medscape Medical News, November 03, 2023
• CV, VTE Risk Not Seen in Derm Studies of JAK Inhibitors "There remains a knowledge gap regarding the risk of JAK inhibitor use and VTE and/or MACE in the dermatologic population," the study authors wrote.
  MDedge News, November 01, 2023
• EADV 2023 Study Finds Ruxolitinib Effective, Safe for Children With AD There were no significant safety signals in the younger pediatric population, and 'no treatment-emergent adverse events suggestive of systemic JAK inhibition,' Dr Lawrence Eichenfield said.
  MDedge News, November 01, 2023
• Study Spotlights Features of Infantile Hemangioma Subset Detailed reports on this patient population are sparse and limited to case reports and small case series.
  Medscape Medical News, October 31, 2023
• Dupilumab-Associated Lymphoid Reactions Require Caution Retrospective study identifies potential for misdiagnosed mycosis fungoides and for dupilumab to fuel cutaneous lymphoid reactions that mimic mycosis fungoides in patients with atopic dermatitis.
  Medscape Medical News, October 30, 2023
• Multicenter HS Study Expanding to More Clinical Sites Among the objectives of the study, which aims to enroll 8000 patients with HS, is to collect biospecimens from patients for translational studies.
  Medscape Medical News, October 27, 2023
• Acne: Study Evaluates the Evidence for Nutraceuticals Despite the many acne treatments available, 'patients may be interested in natural and complementary therapies as either an adjunctive or an alternative to prescription medications,' the authors said.
  MDedge News, October 27, 2023
• EADV 2023 Nemolizumab Promise for Prurigo Nodularis Continues Results from OLYMPIA 1 provide further support for nemolizumab as a potential first-in-class prurigo nodularis treatment; in another study, a JAK inhibitor was beneficial in patients with PN.
  Medscape Medical News, October 25, 2023
• GW Teledermatology Model Expands to Four Underserved Areas Four institutions will receive grants to implement the model, which involved partnering with a local organization to provide an entry point for individuals in areas with limited access to medical care.
  MDedge News, October 25, 2023
• Bullying More Prevalent Among Adolescents With AD Data were collected from adult caregivers of more than 3200 adolescents in the United States.
  Medscape Medical News, October 25, 2023